TY - JOUR
T1 - Treatment of relapsed multiple myeloma
T2 - Evidence-based recommendations
AU - Durer, Ceren
AU - Durer, Seren
AU - Lee, Sarah
AU - Chakraborty, Rajshekhar
AU - Malik, Mustafa Nadeem
AU - Rafae, Abdul
AU - Zar, Muhammad Abu
AU - Kamal, Ahmad
AU - Rosko, Nathaniel
AU - Samaras, Christy
AU - Valent, Jason
AU - Chaulagain, Chakra
AU - Anwer, Faiz
PY - 2020/1
Y1 - 2020/1
N2 - The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies, multiple combination regimens utilizing these agents are being studied with the goal of enhancing disease control, prolonging progression-free survival, and improving overall survival. We, herein, describe a review of FDA-approved regimens for RRMM patients and offer a paradigm in selecting subsequent treatment regimens, focusing on patient specific morbidity, treatment toxicity, and disease-specific characteristics.
AB - The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies, multiple combination regimens utilizing these agents are being studied with the goal of enhancing disease control, prolonging progression-free survival, and improving overall survival. We, herein, describe a review of FDA-approved regimens for RRMM patients and offer a paradigm in selecting subsequent treatment regimens, focusing on patient specific morbidity, treatment toxicity, and disease-specific characteristics.
KW - Evidence-based
KW - Multiple myeloma
KW - Refractory
KW - Relapsed
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85071716943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071716943&partnerID=8YFLogxK
U2 - 10.1016/j.blre.2019.100616
DO - 10.1016/j.blre.2019.100616
M3 - Review article
AN - SCOPUS:85071716943
VL - 39
JO - Blood Reviews
JF - Blood Reviews
SN - 0268-960X
M1 - 100616
ER -